MedTrace Logo

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

NCT06024915 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-12

No results posted yet for this study

Summary

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of metabolic enzyme inhibitors/inducers on in vivo metabolic and elimination of TQ05105 tablets, and the safety of metabolic enzyme inhibitors/inducers combined with TQ05105 tablets.

Conditions

Interventions

DRUG

TQ05105 tablets

TQ05105 is a Janus kinase 2 (JAK2) inhibitor.

DRUG

Itraconazole capsule

Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).

DRUG

Rifampicin Capsule

Rifampicin is a strong inducer of CYP3A.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2024-01-29
Completion
2024-05-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06024915 on ClinicalTrials.gov